title: Fondaparinux - data on efficacy and safety in special situations.
abstract: New anticoagulants promise to have better efficacy, more safety and/or a better manageability than traditional anticoagulants. However, knowledge is limited regarding special situations such as renal insufficiency, obesity, pregnancy, long-term therapy, heparin-induced thrombocytopenia, treatment in patients with mechanical heart valves, use for children, and in patients with a high risk of thromboembolic complications. These situations have rarely or even never been the objective of randomised controlled trials. The purpose of the present article is to summarize and discuss available data on efficacy and safety in these special situations for one of the first new anticoagulants, the indirect factor-Xa inhibitor fondaparinux. Furthermore, we discuss safety in licensed indications and management of bleeding complications and comment on measuring of drug concentration in plasma.
authors: Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, CH-6000 Luzern 16, Switzerland.
authors: Michael
authors: M
authors: Nagler
authors: Michael
authors: M
authors: Haslauer
authors: Walter A
authors: WA
authors: Wuillemin
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D005170:Factor X / Q000037:antagonists & inhibitors*; D005260:Female; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D011134:Polysaccharides / Q000008:administration & dosage* / Q000009:adverse effects*; D011247:Pregnancy; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D011134:Polysaccharides; D005170:Factor X; D000077425:Fondaparinux